Fortress Biotech, Inc. (FBIO): Revenue
$63.26M
Year ended 2025-12-31
$68.47M
Trailing 12 months to 2026-06-30
-5.8%
3-year compound annual growth
+6.8%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $63.26M | +9.7% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $57.67M | -31.8% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $84.51M | +11.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $75.74M | +10.1% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $68.79M | +50.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $45.60M | +24.5% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $36.63M | +36.3% | 2021-04-09, From 2019-01-01 |
| 2018-12-31 | $26.88M | +55.9% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $17.25M | +4.6% | 2019-03-18, From 2017-01-01 |
| 2016-12-31 | $16.48M | n/m | 2018-03-16, From 2016-01-01 |
| 2015-12-31 | $863.0K | n/a | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $0 | n/a | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $0 | n/a | 2016-03-15, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
Compare FBIO, NUVB, TNGX, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗